Immuneering (US:IMRX)2025-05-05 20:17Financial Performance - Cash and cash equivalents as of March 31, 2025, were $35.9 million, a slight decrease from $36.1 million as of December 31, 2024[6]. - Net loss attributable to common stockholders for Q1 2025 was $15.0 million, or $0.42 per share, compared to a net loss of $14.3 million, or $0.49 per share, in Q1 2024[8]. - General and Administrative (G&A) expenses for Q1 2025 were $4.0 million, down from $4.1 million in Q1 2024, reflecting a decrease in employee-related costs[7]. - Research and Development (R&D) expenses for Q1 2025 were $11.5 million, up from $11.2 million in Q1 2024, primarily due to higher clinical costs[6]. - The weighted-average common shares outstanding increased to 35,529,652 in Q1 2025 from 29,370,357 in Q1 2024[8]. Clinical Trials and Developments - The company announced positive data from the ongoing Phase 2a trial of IMM-1-104, including a patient with over 13 months of progression-free survival[3]. - A clinical trial supply agreement was established with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® in non-small cell lung cancer[1]. - The company plans to initiate a Phase 3 trial of IMM-1-104 in first-line pancreatic cancer in 2026[10]. - The company reported a 91% reduction in peak CA 19-9 levels for a pancreatic cancer patient on IMM-1-104 monotherapy[5]. Cash Flow and Funding - The cash runway has been extended into 2026, ensuring sufficient funding for operations[9].